Skip to main content

Candidiasis, Oral

5
Pipeline Programs
8
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 9 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
2
MicafunginPhase 31 trial
micafunginPhase 31 trial
Active Trials
NCT00666185Completed523Est. Feb 2004
NCT00665639Completed454Est. Dec 2004
MSD
MSDIreland - Ballydine
1 program
1
L-743,872Phase 21 trial
Active Trials
NCT00005920Terminated70
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
L-743,872Phase 2
SaNOtize
SaNOtizeBC - Vancouver
1 program
1
Nitric OxidePhase 11 trial
Active Trials
NCT06120816Completed6Est. May 2024
Bristol Myers Squibb
3 programs
NystatinN/ASmall Molecule1 trial
NystatinN/ASmall Molecule1 trial
Amphotericin BPHASE_21 trial
Active Trials
NCT00002293Completed
NCT00002057Completed
NCT00001065Completed70Est. Apr 1998
Sandoz
SandozAustria - Kundl
1 program
Terbinafine hydrochlorideN/A
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
L-743,872PHASE_2
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Roxanes's clotrimazole trochesPHASE_31 trial
Active Trials
NCT02184351Completed187

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Astellasmicafungin
AstellasMicafungin
Boehringer IngelheimRoxanes's clotrimazole troches
Bristol Myers SquibbAmphotericin B
SaNOtizeNitric Oxide

Clinical Trials (8)

Total enrollment: 1,310 patients across 8 trials

NCT00665639Astellasmicafungin

Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

Start: Jun 2004Est. completion: Dec 2004454 patients
Phase 3Completed
NCT00666185AstellasMicafungin

Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis

Start: Aug 2003Est. completion: Feb 2004523 patients
Phase 3Completed
NCT02184351Boehringer IngelheimRoxanes's clotrimazole troches

Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis

Start: May 2001187 patients
Phase 3Completed
NCT00005920MSDL-743,872

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

70 patients
Phase 2Terminated
NCT00001065Bristol Myers SquibbAmphotericin B

A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole

Est. completion: Apr 199870 patients
Phase 2Completed
NCT06120816SaNOtizeNitric Oxide

Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis

Start: Jan 2024Est. completion: May 20246 patients
Phase 1Completed
NCT00002293Bristol Myers SquibbNystatin

A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes

N/ACompleted
NCT00002057Bristol Myers SquibbNystatin

Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.